Ngā hua rapu kaituhi :: APM

1

Statistical issues and challenges in immuno-oncology mā Tai‐Tsang Chen

I whakaputaina 2013

Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
Artigo

Tiaki ki tētahi rārangi

I tiakina i:
2

Milestone Survival: A Potential Intermediate Endpoint for Immune Checkpoint Inhibitors mā Tai‐Tsang Chen

I whakaputaina 2015

Whiwhi kuputuhi katoa
Artigo

Tiaki ki tētahi rārangi

I tiakina i:
3

Differential effects of dosing regimen on the safety and efficacy of dasatinib: retrospective exposure&ndash;response analysis of a Phase III study mā Neil P. Shah, Wang, Amit Roy, Andreas Hochhaus, Kantarjian, Tai‐Tsang Chen

I whakaputaina 2013

Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
Artigo

Tiaki ki tētahi rārangi

I tiakina i:
4

Exposure–Response Relationships of the Efficacy and Safety of Ipilimumab in Patients with Advanced Melanoma mā Feng Yan, Amit Roy, Eric Masson, Tai‐Tsang Chen, Rachel Humphrey, Jeffrey S. Weber

I whakaputaina 2013

Whiwhi kuputuhi katoa
Revisão

Tiaki ki tētahi rārangi

I tiakina i:
5

Efficacy and safety of ipilimumab in metastatic melanoma patients surviving more than 2 years following treatment in a phase III trial (MDX010-20) mā David F. McDermott, John B.A.G. Haanen, Tai‐Tsang Chen, Paul Lorigan, Steven O’Day

I whakaputaina 2013

Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
Artigo

Tiaki ki tētahi rārangi

I tiakina i:
6

Dasatinib early intervention after cytogenetic or hematologic resistance to imatinib in patients with chronic myeloid leukemia mā Alfonso Quintás-Cardama, Jorge E. Cortés, Susan O’Brien, Farhad Ravandi, Gautam Borthakur, David Liu, Eric Bleickardt, Tai‐Tsang Chen, Hagop M. Kantarjian

I whakaputaina 2009

Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
Artigo

Tiaki ki tētahi rārangi

I tiakina i:
7

Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma mā Dirk Schadendorf, F. Stephen Hodi, Caroline Robert, Jeffrey S. Weber, Kim Margolin, Omid Hamid, Debra A. Patt, Tai‐Tsang Chen, David M. Berman, Jedd D. Wolchok

I whakaputaina 2015

Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
Artigo

Tiaki ki tētahi rārangi

I tiakina i:
8

Five-Year Survival Rates for Treatment-Naive Patients With Advanced Melanoma Who Received Ipilimumab Plus Dacarbazine in a Phase III Trial mā Michele Maio, Jean‐Jacques Grob, Steinar Aamdal, Igor Bondarenko, Caroline Robert, L. Thomas, Claus Garbe, Vanna Chiarion‐Sileni, Alessandro Testori, Tai‐Tsang Chen, Marina Tschaika, Jedd D. Wolchok

I whakaputaina 2015

Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
Artigo

Tiaki ki tētahi rārangi

I tiakina i:
9

Recommendations to improve adverse event reporting in clinical trial publications: a joint pharmaceutical industry/journal editor perspective mā Neil Lineberry, Jesse A. Berlin, Bernadette Mansi, Susan Glasser, Michael Berkwits, Christian Klem, Ananya Bhattacharya, Leslie Citrome, Robert E. Enck, John Fletcher, Daniel G. Haller, Tai‐Tsang Chen, Christine Lainé

I whakaputaina 2016

Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
Artigo

Tiaki ki tētahi rārangi

I tiakina i:
10

Relapse-Free Survival as a Surrogate for Overall Survival in the Evaluation of Stage II–III Melanoma Adjuvant Therapy mā Stefan Suciu, Alexander M.M. Eggermont, Paul Lorigan, John M. Kirkwood, Svetomir N. Markovic, Claus Garbe, David Cameron, Srividya Kotapati, Tai‐Tsang Chen, Keith Wheatley, Natalie Ives, Gaetan de Schaetzen, Achmad Efendi, Marc Buyse

I whakaputaina 2017

Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
Revisão

Tiaki ki tētahi rārangi

I tiakina i:
11

Dasatinib in Imatinib-Resistant Philadelphia Chromosome–Positive Leukemias mā Moshe Talpaz, Neil P. Shah, Hagop M. Kantarjian, Nicholas J. Donato, John Nicoll, Ron Paquette, Jorge E. Cortés, Susan O’Brien, Claude Nicaise, Eric Bleickardt, M. Anne Blackwood-Chirchir, Vishwanath R. Iyer, Tai‐Tsang Chen, Fei Huang, Arthur P. DeCillis, Charles L. Sawyers

I whakaputaina 2006

Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
Artigo

Tiaki ki tētahi rārangi

I tiakina i:
12

Efficacy and safety of nivolumab (Nivo) + ipilimumab (Ipi) in patients (pts) with recurrent/metastatic (R/M) cervical cancer: Results from CheckMate 358 mā R. Wendel Naumann, Ana Oaknin, Tim Meyer, José M. López-Picazo, Christopher D. Lao, Yu Jeong Bang, Valentina Boni, William H. Sharfman, J.C. Park, Lot A. Devriese, Kenichi Harano, Christine H. Chung, Suzanne L. Topalian, Kam Zaki, Tai‐Tsang Chen, Junchen Gu, B. Li, Adam Barrows, Andrea Horváth, Kathleen N. Moore

I whakaputaina 2019

Whiwhi kuputuhi katoa
Artigo

Tiaki ki tētahi rārangi

I tiakina i:
13

Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma mā Caroline Robert, L. Thomas, Igor Bondarenko, Steven O’Day, Jeffrey S. Weber, Claus Garbe, Célèste Lebbé, Jean‐François Baurain, Alessandro Testori, Jean‐Jacques Grob, Neville Davidson, Jon Richards, Michele Maio, Axel Hauschild, Wilson H. Miller, Pere Gascón, Michal Lotem, Kaan Harmankaya, Ramy Ibrahim, Stephen Francis, Tai‐Tsang Chen, Rachel Humphrey, Axel Hoos, Jedd D. Wolchok

I whakaputaina 2011

Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
Artigo

Tiaki ki tētahi rārangi

I tiakina i: